KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $73.9 million.

  • Acadia Pharmaceuticals' Free Cash Flow rose 1697.48% to $73.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.1 million, marking a year-over-year decrease of 224.52%. This contributed to the annual value of $157.2 million for FY2024, which is 84400.67% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Free Cash Flow stood at $73.9 million for Q3 2025, which was up 1697.48% from $64.0 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Free Cash Flow ranged from a high of $85.4 million in Q4 2023 and a low of -$76.3 million during Q1 2022
  • Moreover, its 5-year median value for Free Cash Flow was -$727000.0 (2022), whereas its average is $4.8 million.
  • Over the last 5 years, Acadia Pharmaceuticals' Free Cash Flow had its largest YoY gain of 45796.51% in 2023, and its largest YoY loss of 800935.35% in 2023.
  • Quarter analysis of 5 years shows Acadia Pharmaceuticals' Free Cash Flow stood at -$23.1 million in 2021, then decreased by 3.17% to -$23.9 million in 2022, then soared by 457.97% to $85.4 million in 2023, then tumbled by 53.24% to $39.9 million in 2024, then skyrocketed by 85.08% to $73.9 million in 2025.
  • Its Free Cash Flow was $73.9 million in Q3 2025, compared to $64.0 million in Q2 2025 and $20.3 million in Q1 2025.